BPGbio’s mitochondrial disorder drug gets paediatric disease status
BPM31510IV is also a lead candidate to treat solid tumours such as glioblastoma multiforme and pancreatic cancer.
BPGbio Receives FDA Rare Pediatric Disease Designation for its Potential Treatment for Primary Coenzyme Q10 Deficiency
BPGbio received an FDA Rare Pediatric Disease Designation for its potential treatment for primary coenzyme Q10 deficiency.
Business Wire3d
BPGbio to Present Novel Drug Target for Huntington’s Disease and AI Discovered Biomarkers for Alzheimer’s Disease at Society for Neuroscience 2024
BPGbio to present novel Huntington's Disease and Alzheimer's Disease research at the Society for Neuroscience 2024 annual meeting.
Pharmabiz4d
BPGbio receives US FDA rare paediatric disease designation for BPM31510IV for primary coenzyme Q10 deficiency treatment
Boston, Massachusetts Tuesday, October 1, 2024, 14:00 Hrs [IST] ...
Joplin Globe11d
BPGbio and Joslin Diabetes Center Announce Publication Showing Game-Changing Effects of Blue Light in the Reduction of Fat Cells
BPGbio, a pioneering biology-first, AI-powered, clinical-stage biopharma specializing in mitochondrial biology and protein homeostasis, and Joslin Diabetes Center, the world's leading diabetes ...
01Net6d
BPGbio Receives FDA Rare Pediatric Disease Designation for its Potential Treatment for Primary Coenzyme Q10 Deficiency
BOSTON–(BUSINESS WIRE)–#bpgbio—BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that the U.S. Food ...
Joplin Globe19d
BPGbio Appoints John Beeler as SVP of Business Development
BPGbio, Inc., a pioneering biology-first, AI-powered, clinical-stage biopharma specializing in mitochondrial biology and protein homeostasis, today announced the appointment of John Beeler ...
Le Lézard3d
Garmin Ltd. schedules third quarter 2024 earnings call
Garmin Ltd. invites shareholders and investors to listen to its third quarter 2024 earnings conference call on Wednesday, October 30, 2024, at 10:30 a.m. EDT, with executives of Garmin. The call will ...